DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Afinitor; Afinitor 5mg Tablets; Albuterol; Albuterol inhaler; Albuterol nebulizer; Bevacizumab; Celecoxib; Cetuximab; Doxycycline; Doxycycline 100 mg Capsules; EVEROLIMUS; Everolimus; Everolimus (RAD001); Everolimus Oral Product; Glutamine; Hydroxychloroquine; Imatinib; Imatinib Mesylate 400Mg Capsule; Letrozole; Nintedanib; Octreotide; Ofev; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; PFT; Procedure: PFT; RAD001; RAD001 5mg; Rapamycin; Rapamycin, sirolimus; Resveratrol; Saracatinib; Simvastatin; Sirolimus; Sirolimus Oral Product; Sirolimus and Hydroxychloroquine 200 mg; Sirolimus and Hydroxychloroquine 400 mg; Srolimus; Temsirolimus; Valproic Acid; Valproic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02737202 (ClinicalTrials.gov)	April 2016	31/3/2016	Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis	Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis	Pulmonary Lymphangioleiomyomatosis	Drug: saracatinib	Baylor College of Medicine	University of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH)	Terminated	18 Years	65 Years	Female	28	Phase 2	United States
2	NCT02116712 (ClinicalTrials.gov)	August 2014	15/4/2014	The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)	The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)	Pulmonary Lymphangioleiomyomatosis	Drug: Saracatinib	Tony Eissa	University of Texas;University of Cincinnati	Completed	18 Years	65 Years	Both	9	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02737202
(ClinicalTrials.gov)

April 2016

31/3/2016

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Pulmonary Lymphangioleiomyomatosis

Drug: saracatinib

Baylor College of Medicine

University of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH)

Terminated

18 Years

65 Years

Female

Phase 2

United States

NCT02116712
(ClinicalTrials.gov)

August 2014

15/4/2014

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Pulmonary Lymphangioleiomyomatosis

Drug: Saracatinib

Tony Eissa

University of Texas;University of Cincinnati

Completed

18 Years

65 Years

Both

Phase 1

United States